FR2866890B1 - Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant - Google Patents

Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant

Info

Publication number
FR2866890B1
FR2866890B1 FR0402001A FR0402001A FR2866890B1 FR 2866890 B1 FR2866890 B1 FR 2866890B1 FR 0402001 A FR0402001 A FR 0402001A FR 0402001 A FR0402001 A FR 0402001A FR 2866890 B1 FR2866890 B1 FR 2866890B1
Authority
FR
France
Prior art keywords
solution
composition containing
same
purification process
therapeutic use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0402001A
Other languages
English (en)
French (fr)
Other versions
FR2866890A1 (fr
Inventor
Paul Boulange
Sami Chtourou
Stephane Boyer
Roland Schmitthaeusler
Bruno Padrazzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34834103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2866890(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LFB SA filed Critical LFB SA
Priority to FR0402001A priority Critical patent/FR2866890B1/fr
Priority to DE602005002461T priority patent/DE602005002461T2/de
Priority to CA2557174A priority patent/CA2557174C/fr
Priority to PT05731028T priority patent/PT1718673E/pt
Priority to AT05731028T priority patent/ATE373014T1/de
Priority to PCT/FR2005/000416 priority patent/WO2005090402A1/fr
Priority to ES05731028T priority patent/ES2294696T3/es
Priority to DK05731028T priority patent/DK1718673T3/da
Priority to EP05731028A priority patent/EP1718673B1/fr
Priority to PL05731028T priority patent/PL1718673T3/pl
Priority to JP2007500249A priority patent/JP4979571B2/ja
Priority to AU2005223418A priority patent/AU2005223418B2/en
Priority to SI200530101T priority patent/SI1718673T1/sl
Priority to US10/589,825 priority patent/US20070161122A1/en
Priority to BRPI0507886-5A priority patent/BRPI0507886A/pt
Publication of FR2866890A1 publication Critical patent/FR2866890A1/fr
Priority to IL177286A priority patent/IL177286A/en
Priority to CY20071101575T priority patent/CY1107082T1/el
Publication of FR2866890B1 publication Critical patent/FR2866890B1/fr
Application granted granted Critical
Priority to JP2011280288A priority patent/JP2012102115A/ja
Priority to US14/611,460 priority patent/US9611311B2/en
Priority to US15/443,884 priority patent/US10562957B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR0402001A 2004-02-27 2004-02-27 Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant Expired - Lifetime FR2866890B1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FR0402001A FR2866890B1 (fr) 2004-02-27 2004-02-27 Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
JP2007500249A JP4979571B2 (ja) 2004-02-27 2005-02-23 ナノ濾過工程を含むアルブミン精製方法、それを含有する治療用途のための溶液及び組成物
SI200530101T SI1718673T1 (sl) 2004-02-27 2005-02-23 Postopek za ciscenje albumina, ki obsega stopnjo nanofiltracije, raztopina in sestavek za terapevtsko uporabo, ki le-tega vsebuje
PT05731028T PT1718673E (pt) 2004-02-27 2005-02-23 Método de purificação de albumina que inclui uma passo de nanofiltração, uma solução e uma composição para utilização terapêutica que a contenha
AT05731028T ATE373014T1 (de) 2004-02-27 2005-02-23 Einen nanofiltrationsschritt umfassendes verfahren zur aufreinigung von albumin, lösung und zusammensetzung zur therapeutischen anwendung,die dieses enthalten
PCT/FR2005/000416 WO2005090402A1 (fr) 2004-02-27 2005-02-23 Procede de purificaton d’albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
ES05731028T ES2294696T3 (es) 2004-02-27 2005-02-23 Metodo de purificacion de albumina que incluye una etapa de nanofiltracion, solucion y composicion para uso terapeutico que la contiene.
DK05731028T DK1718673T3 (da) 2004-02-27 2005-02-23 Fremgangsmåde til rensning af albumin omfattende et nanofiltreringstrin, oplösning og sammensætning til terapeutisk anvendelse, som indeholder det
EP05731028A EP1718673B1 (fr) 2004-02-27 2005-02-23 Procede de purificaton d' albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
PL05731028T PL1718673T3 (pl) 2004-02-27 2005-02-23 Sposób oczyszczania albuminy obejmujący etap nanofiltracji, roztwór, i zawierająca go kompozycja do terapeutycznego zastosowania
DE602005002461T DE602005002461T2 (de) 2004-02-27 2005-02-23 Einen nanofiltrationsschritt umfassendes verfahren zur aufreinigung von albumin, lösung und zusammensetzung zur therapeutischen anwendung, die dieses enthalten
AU2005223418A AU2005223418B2 (en) 2004-02-27 2005-02-23 Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing same
CA2557174A CA2557174C (fr) 2004-02-27 2005-02-23 Procede de purificaton d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
US10/589,825 US20070161122A1 (en) 2004-02-27 2005-02-23 Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing the same
BRPI0507886-5A BRPI0507886A (pt) 2004-02-27 2005-02-23 método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o
IL177286A IL177286A (en) 2004-02-27 2006-08-03 Albumin purification method comprising a nanofiltration step and solution and composition for therapeutic use containing same
CY20071101575T CY1107082T1 (el) 2004-02-27 2007-12-12 Μεθοδος καθαρισμου αλβουμινης η οποια περιλαμβανει ενα σταδιο νανοδιηθησης, διαλυμα και συνθεση για θεραπευτικη χρηση που περιεχουν την ιδια
JP2011280288A JP2012102115A (ja) 2004-02-27 2011-12-21 ナノ濾過工程を含むアルブミン精製方法、それを含有する治療用途のための溶液及び組成物
US14/611,460 US9611311B2 (en) 2004-02-27 2015-02-02 Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing the same
US15/443,884 US10562957B2 (en) 2004-02-27 2017-02-27 Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0402001A FR2866890B1 (fr) 2004-02-27 2004-02-27 Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant

Publications (2)

Publication Number Publication Date
FR2866890A1 FR2866890A1 (fr) 2005-09-02
FR2866890B1 true FR2866890B1 (fr) 2008-04-04

Family

ID=34834103

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0402001A Expired - Lifetime FR2866890B1 (fr) 2004-02-27 2004-02-27 Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant

Country Status (16)

Country Link
US (3) US20070161122A1 (enExample)
EP (1) EP1718673B1 (enExample)
JP (2) JP4979571B2 (enExample)
AT (1) ATE373014T1 (enExample)
AU (1) AU2005223418B2 (enExample)
BR (1) BRPI0507886A (enExample)
CA (1) CA2557174C (enExample)
CY (1) CY1107082T1 (enExample)
DE (1) DE602005002461T2 (enExample)
DK (1) DK1718673T3 (enExample)
ES (1) ES2294696T3 (enExample)
FR (1) FR2866890B1 (enExample)
IL (1) IL177286A (enExample)
PL (1) PL1718673T3 (enExample)
PT (1) PT1718673E (enExample)
WO (1) WO2005090402A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
FR2894831B1 (fr) 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
WO2012090067A1 (en) 2010-12-30 2012-07-05 Lfb Biotechnologies Glycols as pathogen inactivating agents
FR3004451B1 (fr) * 2013-04-11 2015-12-11 Lab Francais Du Fractionnement Procede de preparation d'une solution de proteine c viralement securisee par une double etape de nanofiltration
EP3119412A1 (en) * 2014-03-21 2017-01-25 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
FR3040882A1 (fr) * 2015-09-10 2017-03-17 Lab Francais Du Fractionnement Composition liquide d'albumine humaine a usage therapeutique
US11640846B2 (en) * 2020-01-30 2023-05-02 Fresenius Medical Care Holdings, Inc. Techniques for modelling and optimizing dialysis toxin displacer compounds
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
CN116744984A (zh) 2020-12-28 2023-09-12 达沃有限公司 包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019919D0 (en) 1990-09-12 1990-10-24 Delta Biotechnology Ltd Purification of proteins
FR2672604B1 (fr) * 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
US5849874A (en) * 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
US5440018A (en) 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
JPH06279296A (ja) * 1993-03-25 1994-10-04 Asahi Chem Ind Co Ltd 血漿分画製剤中から蛋白質会合物の除去方法
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DK1329460T3 (da) * 2000-10-24 2006-07-31 Chemo Sero Therapeut Res Inst Fremgangsmåde til monomerisering af polymerer af humant serum albumin
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
US6806355B2 (en) * 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
DE10211632A1 (de) * 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
JPWO2004089402A1 (ja) * 2003-04-09 2006-07-06 財団法人化学及血清療法研究所 アルブミン製剤の製造方法
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant

Also Published As

Publication number Publication date
AU2005223418B2 (en) 2008-12-18
US10562957B2 (en) 2020-02-18
US20070161122A1 (en) 2007-07-12
DK1718673T3 (da) 2008-01-14
FR2866890A1 (fr) 2005-09-02
DE602005002461D1 (de) 2007-10-25
AU2005223418A1 (en) 2005-09-29
CA2557174C (fr) 2013-04-30
JP2012102115A (ja) 2012-05-31
DE602005002461T2 (de) 2008-06-12
US20150152162A1 (en) 2015-06-04
CY1107082T1 (el) 2012-10-24
ES2294696T3 (es) 2008-04-01
CA2557174A1 (fr) 2005-09-29
PT1718673E (pt) 2007-12-13
US9611311B2 (en) 2017-04-04
JP2007535495A (ja) 2007-12-06
EP1718673B1 (fr) 2007-09-12
IL177286A0 (en) 2006-12-10
IL177286A (en) 2012-08-30
ATE373014T1 (de) 2007-09-15
EP1718673A1 (fr) 2006-11-08
JP4979571B2 (ja) 2012-07-18
PL1718673T3 (pl) 2008-03-31
US20170166626A1 (en) 2017-06-15
WO2005090402A1 (fr) 2005-09-29
BRPI0507886A (pt) 2007-08-07

Similar Documents

Publication Publication Date Title
CY1107082T1 (el) Μεθοδος καθαρισμου αλβουμινης η οποια περιλαμβανει ενα σταδιο νανοδιηθησης, διαλυμα και συνθεση για θεραπευτικη χρηση που περιεχουν την ιδια
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
NZ543467A (en) The severe acute respiratory syndrome coronavirus
EA200401365A1 (ru) Способы лечения илеуса
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
DE602004012745D1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
EP1505990A4 (en) METHOD FOR THE TREATMENT OF HEPATITIS
DE60101575D1 (de) Verfahren zur herstellung von pharmazeutisch annehmbaren salzen des (ss,rs)-s-adenosyl-l-menthionin
WO2005051331A3 (en) Chaperone-based therapy for niemann-pick disease
DE50312660D1 (de) Verfahren zur herstellung und reinigung von 1,7'-dimethyl-2'-propyl-2,5'-bi-1h-benzimidazol
DE602004020632D1 (de) Verfahren zur herstellung einer alpha-1-antitrypsinlösung
DE60004652D1 (de) Verfahren zur herstellung von gabapentin
ATE194167T1 (de) Ein prozess für die herstellung von faktor ix biologischen ursprungs
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
CA2587187A1 (en) Treatment of mastitis with enrofloxacin
SE0201207D0 (sv) A process for production of a regioselective membrane
RU2003118497A (ru) Способ лечения заболеваний слизистых оболочек
JP2004508384A5 (enExample)
RU2001129744A (ru) Способ лечения бациллярных форм туберкулеза легких
RU97103860A (ru) Способ лечения бронхиальной астмы
RU2005107671A (ru) Способ лечения алкогольного делирия
RU2004118697A (ru) Способ лечения вторичной дистрофии роговицы
RU99106494A (ru) Способ профилактики развития эклампсий
RU2007129576A (ru) Способ лечения псориаза
RU2003131987A (ru) Способ лечения хронического холецистита

Legal Events

Date Code Title Description
CL Concession to grant licences
CJ Change in legal form
PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

CA Change of address

Effective date: 20221108

PLFP Fee payment

Year of fee payment: 20